Compare ELUT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 20.9M |
| IPO Year | 2020 | N/A |
| Metric | ELUT | LSTA |
|---|---|---|
| Price | $0.70 | $2.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 242.1K | 24.6K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $21,746,000.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.58 | $1.81 |
| 52 Week High | $4.84 | $4.20 |
| Indicator | ELUT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 46.76 |
| Support Level | $0.66 | $1.85 |
| Resistance Level | $0.72 | $2.16 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 52.63 | 67.78 |
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.